The Natick-based stents giant is calling its new nickel-titanium alloy stent, designed to treat iliac artery disease, the “next generation” of nitinol device. The stent launched in Europe in April.
Boston Scientific Corp. can’t seem to catch a break.
Despite the publication of results from vairous clinical trials that show the superiority of drug-eluting stents — and, in one study, the superiority of the Natick device goliath’s DES over its competitors’ — its share price took a more than 2 percent dive today.
First-quarter sales for Boston Scientific Corp. slipped 1.8 percent to $2.01 billion, compared with $2.05 billion during the same period last year, as it struggles with a large chunk of long-term debt and fights expensive legal battles on a number of fronts.
The Natick-based devices giant plunged into the red, posting a $13 million net loss for the quarter ending March 31, compared with net income of $322 million during the first quarter of 2008.
You’d think after about 20 years, questions about the efficacy of stents would be settled. You’d be wrong.
The outcome of the 10-year court battle is still murky, despite the ruling, which failed to determine “the question of who owes what to whom,” according to the journal.
A three-year trial comparing Abbott Laboratories‘ Xience V drug-eluting stent against its Taxus competitor from Boston Scientific Corp. showed that the Abbott device is much more effective three years after implantation.
The news, announced at an American College of Cardiology conference in Orlando, sent the Natick device goliath’s stock into a slight swoon. The Xience product is already outselling the Taxus, and the news promises to accelerate that trend.
March 16 capped off a rough week for Boston Scientific Corp. and its Taxus stent line.
Two days later, the same day the Natick-based device giant settled a patent infringement case filed by a Texas physician, it was slapped with another by a Hong Kong cardiovascular device maker.